CLAIMS

What is claimed is:

1. Use of an engineered polypeptide comprising a first peptide sequence of 80% or more homology to SEQ ID NO: 3, a second peptide sequence of 80% or more homology to SEQ ID NO: 17, a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain, for the manufacture of a medicament for treating age-related macular degeneration (AMD).

2. The use of claim 1, wherein the first junction region has the sequence of SEQ ID NO: 7 and the second junction region has the sequence of SEQ ID NO: 13 or SEQ ID NO: 14.

3. The use of claim 2, wherein the linker domain comprises a peptide sequence of SEQ ID NO: 11.

4. Use of an engineered polypeptide having a sequence of 80% or more homology to SEQ ID NO: 131 for the manufacture of a medicament for treating age-related macular degeneration (AMD).

5. Use of an engineered polypeptide having a sequence of 90% or more homology to SEQ ID NO: 131 for the manufacture of a medicament for treating age-related macular degeneration (AMD).

6. Use of an engineered polypeptide having a sequence of SEQ ID NO: 131 for the manufacture of a medicament for treating age-related macular degeneration (AMD).

7. Use of an engineered polypeptide comprising the sequence of SEQ ID NO: 21 having one or more amino acid substitutions selected from the group consisting of: L6S, L6T, A289S, A289T, Y380S, Y380T, T16N, D258N, Y334N, D21N, G286N, H355N, A407N, R426N, S428N, G431N, G436N, G441N and G442N for the manufacture of a medicament for treating age-related macular degeneration (AMD).

8. Use of an engineered polypeptide comprising the sequence of SEQ ID NO: 21 having one or more amino acid substitutions selected from the group consisting of: L6S, L6T, A289S, A289T, Y380S, Y380T, T16N, D258N, Y334N, D21N, G286N, H355N, A407N, R426N or S428N for the manufacture of a medicament for treating age-related macular degeneration (AMD).

9. Use of an engineered polypeptide comprising the sequence of SEQ ID NO: 125, SEQ ID NO: 131, or SEQ ID NO: 132 for the manufacture of a medicament for treating age-related macular degeneration (AMD).

10. Use of an engineered polypeptide comprising: a first peptide sequence of one of: SEQ ID NO: 3, SEQ ID NO: 139 or SEQ ID NO: 140; a second peptide sequence of SEQ ID NO: 17, and a linker domain between the first peptide sequence and the second peptide sequence comprising the sequence of: SEQ ID NO: 138 for the manufacture of a medicament for treating age-related macular degeneration (AMD).

11. The use of claim 10, further comprising a first junction region between the first peptide sequence and the linker domain, wherein the first junction region has a sequence of one of: SEQ ID NO: 4-10, and a second junction region between the linker domain and the second peptide sequence, wherein the second junction region has a sequence of one of: SEQ ID NO: 13-16.

12. The use of claim 11, wherein the first junction region has the sequence of SEQ ID NO: 7 and the second junction region has the sequence of SEQ ID NO: 13 or SEQ ID NO: 14.

13. Use of an engineered polypeptide comprising a first peptide sequence of SEQ ID NO: 3, a second peptide sequence of SEQ ID NO: 17, and a linker domain separating the first peptide sequence from the second peptide sequence for the manufacture of a medicament for treating age-related macular degeneration (AMD).

14. Use of an engineered polypeptide comprising a first peptide sequence of 80% or more homology to SEQ ID NO: 3, a second peptide sequence of 80% or more homology to SEQ ID NO: 17, a linker domain separating the first peptide sequence from the second

peptide sequence, for the manufacture of a medicament for treating age-related macular degeneration (AMD).

15. The use of claim 13 or 14, wherein the linker domain comprises an FHL-1 SCR7 Junction coupled to the first peptide sequence, the FHL-1 SCR7 Junction having a peptide sequence of SEQ ID NO: 4 to SEQ ID NO: 10.

16. The use of any one of claims 13-15, wherein the linker domain comprises a CFH SCR6 Junction coupled to the second peptide sequence, the CFH SCR6 Junction having a peptide sequence of SEQ ID NO: 13 to SEQ ID NO: 16.

17. The use of any one of claims 13-16, wherein the linker domain comprises a peptide sequence of SEQ ID NO: 11 or SEQ ID NO: 12.

18. The use of any one of claims 13-17, the engineered polypeptide having an amino acid sequence of any of SEQ ID NO: 18-97, SEQ ID NO: 99-106, SEQ ID NO: 122-125, or SEQ ID NO: 128-132.

19. The use of any one of claims claim 14-18, wherein the first peptide sequence has 95% or more homology to the CFH SCR1-7 peptide sequence of SEQ ID NO: 3, and wherein the second peptide sequence has 95% or more homology to the FHL-1 SCR6-7 peptide sequence of SEQ ID NO: 17.

20. The use of any one of claims 13-19, wherein the linker domain comprises a Gly/Ser linker, a poly-Gly linker or a poly-Ala linker.

21. The use of any one of claims 13-20, wherein the linker domain comprises one of: GGGS, GGGSGGGS, GGGGSGGGS, GGGGSGGGSGGGS, or GGGGSGGGGSGGGGS.

22. Use of a pharmaceutical composition comprising the polypeptide as defined in any one of claims 1 to 21, and a pharmaceutically acceptable excipient for the manufacture of a medicament for the prevention or treatment of age-related macular degeneration (AMD) in a patient.